BioCryst Pharma (BCRX) Reports Q4 Loss Per Share of 6c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.99 --0%
EPS Growth %: -13.3%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -13.3%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.06), $0.17 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $9 million versus the consensus estimate of $4.13 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Berenberg Downgrades Umicore SA (UMI:BB) (UMICY) to Hold
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
